Front Oncol: A real-world, multi-center, observational retrospective study of Durvalumab maintenance therapy after concurrent or continuous radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer

For unresectable stage III non-small cell lung cancer ( NSCLC ), the standard treatment is maintenance therapy with PD-L1 inhibitors (durvalumab) in patients who respond after radiotherapy and chemotherapy (CRT)
.

Phase III study PACIFIC showed that maintenance therapy with PD-L1 inhibitor (durvalumab) in patients who responded after radiotherapy and chemotherapy (CRT) can improve PFS and OS in patients

For unresectable stage III non-small cell lung cancer ( NSCLC ), the standard treatment is maintenance therapy with PD-L1 inhibitors (durvalumab) in patients who respond after radiotherapy and chemotherapy (CRT)

The study retrospectively collected 238 patients who met the criteria from 16 research centers in Italy from September 2018 to March 2020
.

Of the 238 patients, 155 (65.

The study retrospectively collected 238 patients who met the criteria from 16 research centers in Italy from September 2018 to March 2020

22% of patients started durvalumab treatment 42 days after CRT; 78% started 42 days later
.

The median time from CRT to the first durvalumab treatment was 52 days (range 9 245)

22% of patients started durvalumab treatment 42 days after CRT; 78% started 42 days later

The median follow-up time was 14 months (range 2-29)

There was no significant difference in PFS (log-rank p = 0.
2) or OS (log-rank p = 0.
7) between concurrent radiotherapy (cCRT) and continuous radiotherapy (sCRT) combined with durvalumab
.

However, the median PFS of sCRT and cCRT were 13.

There was no significant difference in PFS (log-rank p = 0.

32 cases (20.
6%) had local progression, 46 cases (29.
7%) had systemic metastases; 23 cases (14.
8%) had local and systemic recurrences, and 23 cases (14.
8%) had systemic recurrences
.

The primary metastatic sites are brain, lung (ipsilateral and contralateral), liver and bone

32 cases (20.

76/155 patients (49.
0%) recorded potential immune- related AEs
.
Pneumonia was the most common, causing 11/155 patients (7.
1%) to discontinue the drug
.
immunity

In summary, this real-world multi-center retrospective study showed that Durvalumab maintenance treatment for unresectable stage III non-small cell lung cancer after concurrent or continuous radiotherapy and chemotherapy improves the prognosis of patients
.

In summary, this real-world multi-center retrospective study showed that Durvalumab maintenance treatment for unresectable stage III non-small cell lung cancer improved patient prognosis after concurrent or continuous radiotherapy and chemotherapy
.
This real-world multicenter retrospective study showed that Durvalumab maintenance treatment improved patient prognosis for unresectable stage III non-small cell lung cancer at the same time or after continuous radiotherapy and chemotherapy
.
This real-world multicenter retrospective study showed that Durvalumab maintenance treatment improved patient prognosis for unresectable stage III non-small cell lung cancer at the same time or after continuous radiotherapy and chemotherapy
.

Original source:

Original source:

Bruni A, Scotti V, Borghetti P, et al (2021) A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Front.
Oncol.
11:744956.
doi: 10.
3389/fonc.
2021.
744956

Bruni A, Scotti V, Borghetti P, et al (2021) A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Front.
Oncol.
11:744956.
doi: 10.
3389/fonc.
2021.
744956 leave a message here